Recent Updates
Recently added Catalysts
CMRX

Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016

Key Takeaway: DURHAM, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2016 at 8:30

Full Press Release Details

DURHAM, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2016 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2016, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 49760359. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals in 2014; and earlier-stage clinical candidates, including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.

Contact Data

Stern Investor Relations

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Aug 1, 2016